Establishment Labs reports Q2 EPS (44c), consensus (53c)
Reports Q2 revenue $21.7M, consensus $20.64M. "During the second quarter, we continued to prove the strength of our Women's Health story, driving strong sales growth of over 58%, while regulatory agencies worldwide are placing restrictions on the rest of the industry," said Juan Jose Chacon-Quiros, Chief Executive Officer of Establishment Labs. "We believe this growth trajectory speaks to the clear differentiation and improved safety and aesthetic outcomes of our product portfolio, as well as to the effectiveness of the direct sales force model that we have implemented in Europe and Brazil. In parallel with our ongoing research and development activities, our U.S. FDA clinical trial is progressing with all surgeries now complete in the primary and revision augmentation cohorts and enrollment continuing in the reconstruction cohorts. Importantly, we are implementing a bifurcation strategy in the U.S. that will allow us to submit for the aesthetic cohorts sooner while pursuing approval for the reconstruction cohorts separately. I am very pleased with our progress to this point and I look forward to a strong second half of the year."